ArticleLasers in medical science2026
Red and near-infrared photobiomodulation for burn, hypertrophic, and post-surgical scars: a scoping review of clinical trials.
Article in Lasers in medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeScars may lead to pain, pruritus, functional impairment, and cosmetic concern despite standard therapies. Photobiomodulation (PBM) delivered by light-emitting-diode (LED) or low-level laser therapy (LLLT) has emerged as a non-invasive option to modulate scar remodeling. However, available data derives from small, heterogenous studies. This scoping review evaluates whether red and near-infrared PBM improves clinical outcomes in burn, hypertrophic, and post-surgical scars and summarizes treatment parameters used.
methodsPubMed, Embase, and MEDLINE were searched through October 2025 for randomized or prospective clinical studies in which red (633-670nm) or near-infrared (808-830nm) LED or LLLT was used as monotherapy or where its contribution could be independently assessed. Seven studies (n=297) met inclusion criteria. Data on scar type, wavelength, fluence, regimen, outcomes, and adverse events were extracted.
resultsRed LED improved VSS scores, pigmentation, and thickness in pediatric and adult burn scars, with greater benefits observed in scars < 12 months. In post-surgical scars, red LED reduced induration and improved POSAS scores, with a biphasic dose-response favoring moderate fluence levels. Near-infrared PBM improved color and elasticity in hypertrophic scars and reduced thickness, malleability, pain, and pruritus following hernia repair, thyroidectomy, and blepharoplasty. Across studies, PBM was well tolerated; transient erythema and warmth were most common, with rare blistering at higher fluences.
conclusionRed and near-infrared PBM appears to be a safe, non-invasive adjunct to standard scar management, particularly for early burn and post-operative scars. Larger controlled trials are needed to define optimal wavelength, fluence, timing, and treatment parameters across diverse scar phenotypes and skin phototypes. CLINICAL
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.